Diagnostic Strategies for Prostate Cancer

European Urology, Supplements

Volumn 10, Issue 3, 2011, Pages

  Djavan, Bob ^a   Kazzazi, Amir ^a   Dulabon, Lori ^a   Margreiter, Markus ^b   Farr, Alexander ^b   Handl, Markus Johannes ^b   Lepor, Herbert ^a  

^a NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b MEDICAL UNIVERSITY OF VIENNA   (Austria)

Author keywords

Cancer biomarkers; Diagnostic strategies; Prostate cancer; PSA; Screening

Indexed keywords

BIOLOGICAL MARKER; PROSTATE SPECIFIC ANTIGEN;

ADULT; AGED; CALCULATOR; CANCER SCREENING; COLORECTAL CANCER; CONTROLLED STUDY; CULTURAL ANTHROPOLOGY; HUMAN; LUNG CANCER; MAJOR CLINICAL STUDY; MALE; OVARY CANCER; PRIORITY JOURNAL; PROSTATE CANCER; REVIEW; SENSITIVITY AND SPECIFICITY; VELOCITY;

EID: 79955979021     PISSN: 15699056     EISSN: 18781500     Source Type: Journal    
DOI: 10.1016/j.eursup.2011.03.010     Document Type: Review

References (90)

1. Eyre H., Kahn R., Robertson R.M., et al. Preventing cancer, cardiovascular disease, and diabetes. A common agenda for the American Cancer Society, the American Diabetes Association, and the American Heart Association. Circulation 2004, 109:3244-3255.
2. Bartsch G., Horninger W., Klocker H., et al. Prostate cancer mortality after introduction of prostate specific antigen mass screening in the federal state of Tyrol, Austria. Urology 2001, 58:417-424.
3. Schröder F.H., Hugosson J., Roobol M.J., et al. Screening and prostate-cancer mortality in a randomized European study. N Engl J Med 2009, 360:1320-1328.
4. Andriole G.L., Crawford E.D., Grubb R.L., et al. Mortality results from a randomized prostate-cancer screening trial. N Engl J Med 2009, 360:1310-1319.
5. Anast J.W., Andriole G.L., Bismar T.A., Yan Y., Humphrey P.A. Relating biopsy and clinical variables to radical prostatectomy findings: can insignificant and advanced prostate cancer be predicted in a screened population?. Urology 2004, 64:544-550.
6. Gilliland F.D., Hunt W.C., Key C.R. Improving survival for patients with prostate cancer diagnosed in the prostate specific antigen era. Urology 1996, 48:67-71.
7. Paquette E.L., Connelly R.R., Sesterhenn I.A., et al. Improvements in pathologic staging for African American men undergoing radical retropubic prostatectomy during the prostate specific antigen era: implications for screening a high-risk group for prostate carcinoma. Cancer 2001, 92:2673-2679.
8. Canfield S. Annual screening for prostate cancer did not reduce mortality from prostate cancer. Evid Based Med 2009, 14:104-105.
9. Catalona W.J., Smith D.S., Ratliff T.L., Basler J.W. Detection of organ-confined prostate cancer is increased through prostate specific antigen-based screening. JAMA 1993, 270:948-954.
10. Sun L., Gancarczyk K., Paquette E.L., et al. Introduction to the Department of Defense Center for Prostate Disease Research Multicenter National Prostate Cancer Database and analysis in the PSA era. Urol Oncol 2001, 203-209.
11. Stephenson R.A., Stanford J.L. Population-based prostate cancer trends in the United States: patterns of change in the era of prostate specific antigen. World J Urol 1997, 15:331-335.
12. Roehl K.A., Han M., Ramos C.G., Antenor J.A.V., Catalona W.J. Cancer progression and survival rates following anatomical radical retropubic prostatectomy in 3,478 consecutive patients: long-term results. J Urol 2004, 172:910-914.
13. Catalona W.J., Smith D.S., Ornstein D.K. Prostate cancer detection in men with serum PSA concentrations of 2.6 ng/ml to 4.0 ng/ml and benign prostate examination. Enhancement of specificity with free PSA measurements. JAMA 1997, 277:1452-1455.
14. Horninger W., Cheli C.D., Babaian R.J., et al. Complexed prostate specific antigen for early detection of prostate cancer in men with serum prostate specific antigen levels of 2 to 4 nanograms per millilitre. Urology 2002, 60:31-35.
15. Oesterling J.E., Jacobsen S.J., Chute C.G., et al. Serum prostate-specific antigen in a community-based population of healthy men: established age-specific reference ranges. JAMA 1993, 270:860-864.
16. Morgan T.O., Jacobsen S.J., McCarthy W.F., et al. Age-specific reference ranges for prostate-specific antigen in black men. N Engl J Med 1996, 335:304-310.
17. Labrie F., Candas B., Dupont A., et al. Screening decreases prostate cancer death: first analysis of the 1988 Quebec prospective randomized controlled trial. Prostate 1999, 38:83-91.
18. Newschaffer C.J., Otani K., McDonald M.K., Penberthy L.T. Causes of death in elderly prostate cancer patients and in a comparison nonprostate cancer cohort. J Natl Cancer Inst 2009, 92:613-621.
19. Carroll P, Prostate-Specific Antigen Best Practice Statement: 2009 Update (American Urological Association Education and Research, Inc, 2009), accessed April 2011. http://www.auanet.org/content/guidelines-and-quality-care/clinical-guidelines/main-reports/psa09.pdf.
20. Brawer M.K., Cheli C.D., Neaman I.E., et al. Complexed prostate-specific antigen provides significant enhancement of specificity compared with total prostate-specific antigen for detecting prostate cancer. J Urol 2000, 163:1476-1480.
21. Yokomizo Y., Miyoshi Y., Nakaigawa N., et al. Free PSA/total PSA ratio increases the detection rate of prostate cancer in twelve-core biopsy. Urol Int 2009, 82:280-285.
22. Djavan B., Zlotta A., Kratzik C., et al. PSA, PSA density, PSA density of transitional zone, free/total PSA ratio, and PSA velocity for early detection of prostate cancer in men with serum PSA 2.5 to 4.0 ng/ml. Urology 1999, 54:517-522.
23. Catalona W.J., Loeb S., Han M. Viewpoint: expanding prostate cancer screening. Ann Intern Med 2006, 144:441-443.
24. Catalona W.J., Partin A.W., Slawin K.M., et al. Use of percentage of free prostate-specific antigen to enhance differentiation of prostate cancer from benign prostatic disease: a prospective multicenter clinical trial. JAMA 1998, 279:1542-1547.
25. Djavan B., Zlotta A.R., Byttebier G., et al. Prostate-specific antigen density of the transitional zone for early detection of prostate cancer. J Urol 1998, 160:411-419.
26. Djavan B., Zlotta A., Remzi M., et al. Optimal predictors of prostate cancer on repeat prostate biopsy: a prospective study of 1051 patients. J Urol 2000, 163:1144-1149.
27. Catalona W.J., Partin A.W., Finlay J.A., et al. Use of percentage of free prostate-specific antigen to identify men at high risk of prostate cancer when PSA levels are 2.51 to 4 ng/ml and digital rectal examination is not suspicious for prostate cancer: an alternative model. Urology 1999, 54:220-224.
28. Piironen T., Pettersson K., Suonpaa M., et al. In vitro stability of free prostate-specific antigen (PSA) and prostate-specific antigen (PSA) complexed to alpha 1-antichymotrypsin in blood samples. Urology 1996, 48(Suppl 6A):81-87.
29. Ahyai S.A., Isbarn H., Karakiewicz P.I. The presence of prostate cancer on saturation biopsy can be accurately predicted. BJU Int 2010, 105:636-641.
30. Benson M.C., Whang I.S., Olsson C.A., McMahon D.J., Cooner W.H. The use of prostate specific antigen density to enhance the predictive value of intermediate levels of serum prostate specific antigen. J Urol 1992, 147:817-821.
31. Kuriyama M., Uno H., Watanabe H., Yamanaka H., Saito Y., Shida K. Determination of reference values for total PSA, F/T and PSAD according to prostatic volume in Japanese prostate cancer patients with slightly elevated serum PSA levels. Jpn J Clin Oncol 1999, 29:617-622.
32. Borer J.G., Sherman J., Solomon M.C., Plawker M.W., Macchia R.J. Age specific prostate specific antigen reference ranges: population specific. J Urol 1998, 159:444-448.
33. Ferreira M.D., Koff W.J. Assessment of serum level of prostate-specific antigen adjusted for the transition zone volume in early detection of prostate cancer. Int Braz J Urol 2005, 31:137-145.
34. Carter H.B., Morrell C.H., Pearson J.D., et al. Estimation of prostatic growth using serial prostate-specific antigen measurements in men with and without prostate disease. Cancer Res 1992, 52:3323-3328.
35. Ornstein D.K., Smith D.S., Rao G.S., Basler J.W., Ratliff T.L., Catalona W.J. Biological variation of total, free and percent free serum prostate specific antigen levels in screening volunteers. J Urol 1997, 157:2179-2182.
36. Porter J.R., Hayward R., Brawer M.K. The significance of short term PSA change in men undergoing ultrasound guided prostate biopsy. J Urol 1994, 264(Suppl 1):9-17.
37. Nixon R.G., Meyer G.E., Blase A.B., Gold M.H., Brawer M.K. Comparison of three investigational assays for the free form of prostate specific antigen. J Urol 1998, 160:420-425.
38. Mikolajczyk S.D., Millar L.S., Wang T.J., et al. A precursor form of prostate-specific antigen is more highly elevated in prostate cancer compared with benign transition zone prostate tissue. Cancer Res 2000, 60:756-759.
39. Jansen F.H., van Schaik R.H.N., Kurstjens J., et al. Prostate-specific antigen (PSA) isoform p2PSA in combination with total PSA and free PSA improves diagnostic accuracy in prostate cancer detection. Eur Urol 2010, 57:921-927. comment 928-9.
40. Figueroa J.A., De Raad S., Tadlock L., Speights V.O., Rinehart J.J. Differential expression of insulin-like growth factor binding proteins in high versus low Gleason score prostate cancer. J Urol 1998, 159:1379-1383.
41. Stattin P., Bylund A., Rinaldi S., et al. Plasma insulin-like growth factor-I, insulin-like growth factor-binding proteins, and prostate cancer risk: a prospective study. J Natl Cancer Inst 2000, 92:1910-1917.
42. Thomas J.A., Antonelli J.A., Lloyd J.C., et al. Effect of intermittent fasting on prostate cancer tumor growth in a mouse model. Prostate Cancer Prostatic Dis 2010, 13:350-355.
43. Schedlich L.J., Benetts B., Morris B.J. Primary structure of a human glandular kallikrein gene. DNA 1987, 6:429-437.
44. Darson M.F., Pacelli A., Roche P., et al. Human glandular kallikrein 2 expression in prostate adenocarcinoma and lymph node metastases. Urology 1999, 53:939-944.
45. Partin A.W., Catalona W.J., Smith D.S. Use of human glandular kallikrein 2 for detection of prostate cancer: preliminary analysis. Urology 1999, 54:839-845.
46. Becker C., Piironen T., Pettersson K., Hugosson J., Lilja H. Clinical value of human glandular kallikrein 2 and free and total prostate specific antigen in serum form a population of men with prostate specific antigen levels 3 ng/ml or greater. Urology 2000, 55:694-699.
47. Benchikh A., Savage C., Cronin A., et al. A panel of kallikrein markers can predict outcome of prostate biopsy following clinical work-up: an independent validation study from the European Randomized Study of Prostate Cancer screening, France. BMC Cancer 2010, 10:635.
48. Nurmikko P., Pettersson K., Piironen T., Hugosson J., Lilja H. Discrimination of prostate cancer from benign disease by plasma measurement of intact, free prostate specific antigen lacking an internal cleavage site at Lys145-Lys146. Clin Chem 2001, 47:1415-1423.
49. Steuber T., Nurmikko P., Haese A., et al. Discrimination of benign from malignant prostatic disease by selective measurements of single chain, intact free prostate specific antigen. J Urol 2002, 168:1917-1922.
50. Linton H.J., Marks L.S., Millar L.S., Knott C.L., Rittenhouse H.G., Mikolajczyk S.D. Benign prostate specific antigen (BPSA) in serum is increased in benign prostate disease. Clin Chem 2003, 49:253-259.
51. Denham J.W., Steigler A., Wilcox C., et al. Why are pretreatment prostate-specific antigen levels and biochemical recurrence poor predictors of prostate cancer survival? Cancer 2009, 115:4477-4487.
52. Mikolajczyk S.D., Millar L.S., Marker K.M., et al. Seminal plasma contains "BPSA" a molecular form of prostate specific antigen that is associated with benign prostatic hyperplasia. Prostate 2000, 45:271-276.
53. Klausner A.P., Anderson B.B., Espy P.G., et al. Long term prostate-specific antigen trends following subcapsular prostatectomy. Can J Urol 2010, 17:5442-5446.
54. Mikolajczyk S.D., Marker K.M., Millar L.S., et al. A truncated precursor form of prostate specific antigen is a more specific serum marker of prostate cancer. Cancer Res 2001, 61:6958-6963.
55. Mikolaiczyk S.D., Rittenhouse H.G. Pro PSA: a more cancer specific form of prostate specific antigen for the early detection of prostate cancer. Keio J Med 2003, 52:86-91.
56. Catalona W.J., Bartsch G., Rittenhouse H.G., et al. Serum pro prostate specific antigen improves cancer detection compared to free and complexed prostate specific antigen in men with prostate specific antigen 2.4-4 ng/ml. J Urol 2003, 170:2181-2185.
57. Tosoian J., Loeb S. PSA and beyond: the past, present, and future of investigative biomarkers for prostate cancer. ScientificWorld Journal 2010, 10:1919-1931.
58. Herwig R., Horninger W., Rehder P., et al. Ability of PSA-positive circulating macrophages to detect prostate cancer. Prostate 2005, 62:290-298.
59. Herwig R., Mitteregger D., Djavan B., et al. Detecting prostate cancer by intracellular macrophage prostate-specific antigen (PSA): a more specific and sensitive marker than conventional serum total PSA. Eur J Clin Invest 2008, 38:430-437.
60. Jaraj S.J., Augsten M., Häggarth L., et al. GAD1 is a biomarker for benign and malignant prostatic tissue. Scand J Urol Nephrol 2011, 45:39-45.
61. Häggarth L., Hägglöf C., Jaraj S.J., et al. Diagnostic biomarkers of prostate cancer. Scand J Urol Nephrol 2011, 45:60-67.
62. Harden S.V., Guo Z., Epstein J.L., Sidransky D. Quantitative GSTP1 methylation clearly distinguishes benign prostatic tissue and limited prostatic adenocarcinoma. J Urol 2003, 169:1138-1142.
63. Steiner I., Jung K., Schatz P., Horns T., et al. Gene promoter methylation and its potential relevance in early prostate cancer diagnosis. Pathobiology 2010, 77:260-266.
64. Muller M., Goessl C., Krause H., Miller K. Molecular diagnostics in urologic oncology. Detection of nucleic acids in urine samples. Urologe A 2003, 42:660-668.
65. Bantis A., Patsouris E., Gonidi M., et al. Telomerase RNA expression and DNA ploidy as prognostic markers of prostate carcinomas. Tumori 2009, 95:744-752.
66. Verhaegh G.W., van Bokhoven A., Smit F., Schalken J.A., Bussemakers M.J. Isolation and characterization of the promoter of the human prostate cancer-specific DD3 gene. J Biol Chem 2000, 275:37496-37503.
67. Liang P., Pardee A.B. Differential display of eukaryotic messenger RNA by means of polymerase chain reaction. Science 1992, 257:967-971.
68. Makarov D.V., Loeb S., Getzenberg R.H., Partin A.W. Biomarkers for prostate cancer. Ann Rev Med 2009, 60:139-151.
69. Kollermann J., Kempkensteffen C., Helpap B., et al. Impact of hormonal therapy on the detection of promoter hypermethylation of the detoxifying glutathione-S-transferase P1 gene (GSTP1) in prostate cancer. BMC Urol 2006, 6-15.
70. Ploussard G., de la Taille A. Urine biomarkers in prostate cancer. Nat Rev Urol 2010, 7:101-109.
71. Klecka J., Holubec L., Pesta M., et al. Differential display code 3 (DD3/PCA3) in prostate cancer diagnosis. Anticancer Res 2010, 30:665-670.
72. Floriano-Sánchez E., Cárdenas-Rodríguez N., Castro-Marín M., et al. DD3(PCA3) gene expression in cancer and prostatic hyperplasia. Clin Invest Med 2009, 32:E258.
73. Ruiz-Aragón J., Márquez-Peláez S. Assessment of the PCA3 test for prostate cancer diagnosis: a systematic review and meta-analysis. Actas Urol Esp 2010, 34:346-355.
74. Jeronimo C., Nomoto S., Caballero O.L., et al. Mitochondrial mutations in early stage prostate cancer and bodily fluids. Oncogene 2001, 20:5195-5198.
75. Richardson T., McCanse W., Casale G.P. Tissue-based quantification of 8-hydroxy-2'-deoxyguanosine in human prostate biopsies using quantitative fluorescence imaging analysis. Urology 2009, 74:1174-1179.
76. Wang H., Xi X., Kong X., Huang G., Ge G. The expression and significance of survivin mRNA in urinary bladder carcinomas. J Cancer Res Clin Oncol 2004, 130:487-490.
77. Fisker N., Westergaard M., Hansen H.F., Hansen J.B. Survivin mRNA antagonists using locked nucleic acid, potential for molecular cancer therapy. Nucleosides Nucleotides Nucleic Acids 2007, 26:1427-1430.
78. Dudderidge T.J., Kelly J.D., Wollenschlaeger A., et al. Diagnosis of prostate cancer by detection of minichromosome maintenance 5 protein in urine sediments. Br J Cancer 2010, 103:701-707.
79. Tanaka M., Tanaka T., Matsuzaki S., et al. Rapid and quantitative detection of human septin family Bradeion as a practical diagnostic method of colorectal and urologic cancers. Med Sci Monit 2003, 9:MT61-MT68.
80. Lombardo M.E., Hudson P.B. Preliminary evaluation of 5α-reductase type 2 in urine as potential marker for prostate disease. Steroids 1997, 62:682-685.
81. Prior C., Guillen-Grima F., Robles J.E. Use of a combination of biomarkers in serum and urine to improve detection of prostate cancer. World J Urol 2010, 28:681-686.
82. Thompson I.M., Ankerst D.P., Chi C., et al. Assessing prostate cancer risk: results from the Prostate Cancer Prevention Trial. J Natl Cancer Inst 2006, 98:529-534.
83. Ngo T.C., Turnbull B.B., Lavori P.W., Presti J.C. The prostate cancer risk calculator from the Prostate Cancer Prevention Trial underestimates the risk of high grade cancer in contemporary referral patients. J Urol 2011, 185:483-488.
84. Nguyen C.T., Yu C., Moussa A., et al. Performance of prostate cancer prevention trial risk calculator in a contemporary cohort screened for prostate cancer and diagnosed by extended prostate biopsy. J Urol 2010, 183:529-533.
85. Roobol M.J., Steyerberg E.W., Kranse R., et al. A risk-based strategy improves prostate-specific antigen-driven detection of prostate cancer. Eur Urol 2010, 57:79-85.
86. Steyerberg E.W., Roobol M.J., Kattan M.W., van der Kwast T.H., de Koning H.J., Schröder F.H. Prediction of indolent prostate cancer: validation and updating of a prognostic nomogram. J Urol 2007, 177:107-112.
87. Kranse R., Roobol M.J., Schröder F.H. A graphical device to represent the outcomes of a logistic regression analysis, an illustration of its possible use in prostate cancer screening and prostate cancer treatment counseling. Prostate 2008, 68:1674-1680.
88. Djavan B., Remzi M., Zlotta A.R., et al. Novel artificial neural network for early detection of prostate cancer. J Clin Oncol 2002, 20:921-929.
89. Stephan C., Xu C., Cammann H., et al. Assay-specific artificial neural networks for five different PSA assays and populations with PSA 2-10 ng/ml in 4,480 men. World J Urol 2007, 25:95-103.
90. Smith R.A., Von Eschenbach A.C., Wender R., et al. American Cancer Society guidelines for early detection of cancer: update of early detection guidelines for prostate, colorectal and endometrial cancers. CA Cancer J Clin 2001, 51:38-75.